secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-06-17T20:00:15+00:00
Accession:  0001193125-26-274093
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Damora Therapeutics shareholders elect directors, approve say-on-pay and E&Y ratification at 2026 annual meeting
--------------------------------------------------------------------------------

- Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.
- Advisory say-on-pay approved: 51,401,988 for, 3,546 against, 27,018 abstain.
- Say-on-frequency: one-year option received 50,913,167 votes; Board adopts annual frequency.
- Ratified Ernst & Young as auditor for FY2026: 54,977,317 for, 5,640 against, 26,981 abstain.
- Quorum of 55,009,938 shares out of 60,303,212 outstanding was represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/dmra-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-274093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer